In fact, the price of such vouchers has been climbing steadily in recent months, according to public disclosures surrounding ...
The Priority Review Voucher (PRV) program is designed to incentivize rare disease drug development.
For Zevra Therapeutics, last year’s approval of the rare lysosomal storage disorder drug Miplyffa appears to be the gift that keeps on giving. After receiving a rare pediatric disease priority review ...
U.S. President Biden signed a bill last Thursday postponing the sunset date of the rare pediatric disease Priority Review Voucher (PRV) program from September 30, 2024, to December 20, 2024. The bill, ...
Renewing hopes of restoring the rare pediatric disease priority review voucher (RPD PRV) program that expired at the end of 2024, the House Energy and Commerce Committee voted 47-0 Sept. 17 to advance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback